Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

Anindita Chakrabarty, Violeta Sánchez, María G. Kuba, Cammie Rinehart, Carlos L. Arteaga

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell lines with constitutive PI3K activation. Treatment with XL147 resulted in dose-dependent inhibition of cell growth and levels of pAKT and pS6, signal transducers in the PI3K/AKT/TOR pathway. In HER2-overexpressing cells, inhibition of PI3K was followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors suppressed the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2 + cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6. Trastuzumab and lapatinib each synergized with XL147 for inhibition of pAKT and growth of established BT474 xenografts. These data suggest that PI3K antagonists will inhibit AKT and relieve suppression of receptor tyrosine kinase expression and their activity. Relief of this feedback limits the sustained inhibition of the PI3K/AKT pathway and attenuates the response to these agents. As a result, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents. In patients with HER2- overexpressing breast cancer, PI3K inhibitors should be used in combination with HER2/HER3 antagonists.

Original languageEnglish (US)
Pages (from-to)2718-2723
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number8
DOIs
StatePublished - Feb 21 2012

Fingerprint

Phosphatidylinositol 3-Kinases
Up-Regulation
Receptor Protein-Tyrosine Kinases
Breast Neoplasms
Growth
Transducers
Heterografts
Small Interfering RNA
Cell Death
Transcription Factors
Phosphorylation
Cell Line
Messenger RNA
XL147

Keywords

  • Signaling
  • Targeted therapy

ASJC Scopus subject areas

  • General

Cite this

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. / Chakrabarty, Anindita; Sánchez, Violeta; Kuba, María G.; Rinehart, Cammie; Arteaga, Carlos L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 8, 21.02.2012, p. 2718-2723.

Research output: Contribution to journalArticle

@article{a361528a22754e55b6e68255aa03e83f,
title = "Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors",
abstract = "We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell lines with constitutive PI3K activation. Treatment with XL147 resulted in dose-dependent inhibition of cell growth and levels of pAKT and pS6, signal transducers in the PI3K/AKT/TOR pathway. In HER2-overexpressing cells, inhibition of PI3K was followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors suppressed the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2 + cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6. Trastuzumab and lapatinib each synergized with XL147 for inhibition of pAKT and growth of established BT474 xenografts. These data suggest that PI3K antagonists will inhibit AKT and relieve suppression of receptor tyrosine kinase expression and their activity. Relief of this feedback limits the sustained inhibition of the PI3K/AKT pathway and attenuates the response to these agents. As a result, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents. In patients with HER2- overexpressing breast cancer, PI3K inhibitors should be used in combination with HER2/HER3 antagonists.",
keywords = "Signaling, Targeted therapy",
author = "Anindita Chakrabarty and Violeta S{\'a}nchez and Kuba, {Mar{\'i}a G.} and Cammie Rinehart and Arteaga, {Carlos L.}",
year = "2012",
month = "2",
day = "21",
doi = "10.1073/pnas.1018001108",
language = "English (US)",
volume = "109",
pages = "2718--2723",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

AU - Chakrabarty, Anindita

AU - Sánchez, Violeta

AU - Kuba, María G.

AU - Rinehart, Cammie

AU - Arteaga, Carlos L.

PY - 2012/2/21

Y1 - 2012/2/21

N2 - We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell lines with constitutive PI3K activation. Treatment with XL147 resulted in dose-dependent inhibition of cell growth and levels of pAKT and pS6, signal transducers in the PI3K/AKT/TOR pathway. In HER2-overexpressing cells, inhibition of PI3K was followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors suppressed the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2 + cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6. Trastuzumab and lapatinib each synergized with XL147 for inhibition of pAKT and growth of established BT474 xenografts. These data suggest that PI3K antagonists will inhibit AKT and relieve suppression of receptor tyrosine kinase expression and their activity. Relief of this feedback limits the sustained inhibition of the PI3K/AKT pathway and attenuates the response to these agents. As a result, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents. In patients with HER2- overexpressing breast cancer, PI3K inhibitors should be used in combination with HER2/HER3 antagonists.

AB - We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell lines with constitutive PI3K activation. Treatment with XL147 resulted in dose-dependent inhibition of cell growth and levels of pAKT and pS6, signal transducers in the PI3K/AKT/TOR pathway. In HER2-overexpressing cells, inhibition of PI3K was followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors suppressed the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2 + cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6. Trastuzumab and lapatinib each synergized with XL147 for inhibition of pAKT and growth of established BT474 xenografts. These data suggest that PI3K antagonists will inhibit AKT and relieve suppression of receptor tyrosine kinase expression and their activity. Relief of this feedback limits the sustained inhibition of the PI3K/AKT pathway and attenuates the response to these agents. As a result, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents. In patients with HER2- overexpressing breast cancer, PI3K inhibitors should be used in combination with HER2/HER3 antagonists.

KW - Signaling

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84857417355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857417355&partnerID=8YFLogxK

U2 - 10.1073/pnas.1018001108

DO - 10.1073/pnas.1018001108

M3 - Article

VL - 109

SP - 2718

EP - 2723

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -